Jiangsu Recbio Technology (DB:G93) - Stock Price, News & Analysis

G93 Stock Overview

A vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China.

About the company

G93 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have meaningful revenue (CN¥30M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Jiangsu Recbio Technology Co., Ltd. Competitors

Formycon

XTRA:FYB

€916.4m

2invest

XTRA:2INV

€60.9m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€117.0m

Price History & Performance

Summary of all time highs, changes and price drops for Jiangsu Recbio Technology
Historical stock prices
Current Share Price	HK$0.94
52 Week High	HK$1.04
52 Week Low	HK$0.81
Beta	-0.17
11 Month Change	-6.94%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-9.34%

Recent updates

Shareholder Returns

	G93	DE Biotechs	DE Market
7D	2.1%	2.9%	1.5%
1Y	n/a	-16.9%	6.2%

Return vs Industry: Insufficient data to determine how G93 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how G93 performed against the German Market.

Price Volatility

Is G93's price volatile compared to industry and market?
G93 volatility
G93 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: G93 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine G93's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	507	Yong Liu	www.recbio.cn

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage.

Jiangsu Recbio Technology Co., Ltd. Fundamentals Summary

How do Jiangsu Recbio Technology's earnings and revenue compare to its market cap?
G93 fundamental statistics
Market cap	€460.74m
Earnings (TTM)	-€69.61m
Revenue (TTM)	€3.85m

119.5x

P/S Ratio

-6.6x

P/E Ratio

Is G93 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
G93 income statement (TTM)
Revenue	CN¥30.38m
Cost of Revenue	CN¥8.04m
Gross Profit	CN¥22.34m
Other Expenses	CN¥570.88m
Earnings	-CN¥548.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.14
Gross Margin	73.54%
Net Profit Margin	-1,805.78%
Debt/Equity Ratio	81.5%

How did G93 perform over the long term?

See historical performance and comparison

Jiangsu Recbio Technology DB:G93 Stock Report